An evaluation of tamoxifen dose escalation in advanced breast cancer

A. Goldhirsch, R. A. Joss, U. Leuenberger, F. Cavalli, H. J. Ryssel, K. W. Brunner

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We escalated the dose of tamoxifen (TAM) to 30 or 40 mg daily in 23 patients who had experienced remission or stable disease (NC) under prior treatment with TAM 20 mg daily. One patient, whose bone and soft tissue disease had previously been stabilized under TAM 20 mg daily for 13 months, showed a partial remission (PR) lasting for 6 months. In 14 patients (64%) the disease remained stable for a median duration of 6 months (1.5-18 + mos.). Subjective improvement was noted in nine patients (39%), including the patient with PR and another one with progressive disease (PD). We conclude that dose escalation has no relevant activity in patients failing prior treatment with conventional doses of TAM.

Original languageEnglish
Pages (from-to)501-503
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume5
Issue number5
Publication statusPublished - 1982

Fingerprint

Tamoxifen
Breast Neoplasms
Bone and Bones
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Goldhirsch, A., Joss, R. A., Leuenberger, U., Cavalli, F., Ryssel, H. J., & Brunner, K. W. (1982). An evaluation of tamoxifen dose escalation in advanced breast cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 5(5), 501-503.

An evaluation of tamoxifen dose escalation in advanced breast cancer. / Goldhirsch, A.; Joss, R. A.; Leuenberger, U.; Cavalli, F.; Ryssel, H. J.; Brunner, K. W.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 5, No. 5, 1982, p. 501-503.

Research output: Contribution to journalArticle

Goldhirsch, A, Joss, RA, Leuenberger, U, Cavalli, F, Ryssel, HJ & Brunner, KW 1982, 'An evaluation of tamoxifen dose escalation in advanced breast cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 5, no. 5, pp. 501-503.
Goldhirsch, A. ; Joss, R. A. ; Leuenberger, U. ; Cavalli, F. ; Ryssel, H. J. ; Brunner, K. W. / An evaluation of tamoxifen dose escalation in advanced breast cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1982 ; Vol. 5, No. 5. pp. 501-503.
@article{83759993bdc44acd9449f79507e42318,
title = "An evaluation of tamoxifen dose escalation in advanced breast cancer",
abstract = "We escalated the dose of tamoxifen (TAM) to 30 or 40 mg daily in 23 patients who had experienced remission or stable disease (NC) under prior treatment with TAM 20 mg daily. One patient, whose bone and soft tissue disease had previously been stabilized under TAM 20 mg daily for 13 months, showed a partial remission (PR) lasting for 6 months. In 14 patients (64{\%}) the disease remained stable for a median duration of 6 months (1.5-18 + mos.). Subjective improvement was noted in nine patients (39{\%}), including the patient with PR and another one with progressive disease (PD). We conclude that dose escalation has no relevant activity in patients failing prior treatment with conventional doses of TAM.",
author = "A. Goldhirsch and Joss, {R. A.} and U. Leuenberger and F. Cavalli and Ryssel, {H. J.} and Brunner, {K. W.}",
year = "1982",
language = "English",
volume = "5",
pages = "501--503",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - An evaluation of tamoxifen dose escalation in advanced breast cancer

AU - Goldhirsch, A.

AU - Joss, R. A.

AU - Leuenberger, U.

AU - Cavalli, F.

AU - Ryssel, H. J.

AU - Brunner, K. W.

PY - 1982

Y1 - 1982

N2 - We escalated the dose of tamoxifen (TAM) to 30 or 40 mg daily in 23 patients who had experienced remission or stable disease (NC) under prior treatment with TAM 20 mg daily. One patient, whose bone and soft tissue disease had previously been stabilized under TAM 20 mg daily for 13 months, showed a partial remission (PR) lasting for 6 months. In 14 patients (64%) the disease remained stable for a median duration of 6 months (1.5-18 + mos.). Subjective improvement was noted in nine patients (39%), including the patient with PR and another one with progressive disease (PD). We conclude that dose escalation has no relevant activity in patients failing prior treatment with conventional doses of TAM.

AB - We escalated the dose of tamoxifen (TAM) to 30 or 40 mg daily in 23 patients who had experienced remission or stable disease (NC) under prior treatment with TAM 20 mg daily. One patient, whose bone and soft tissue disease had previously been stabilized under TAM 20 mg daily for 13 months, showed a partial remission (PR) lasting for 6 months. In 14 patients (64%) the disease remained stable for a median duration of 6 months (1.5-18 + mos.). Subjective improvement was noted in nine patients (39%), including the patient with PR and another one with progressive disease (PD). We conclude that dose escalation has no relevant activity in patients failing prior treatment with conventional doses of TAM.

UR - http://www.scopus.com/inward/record.url?scp=0020403763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020403763&partnerID=8YFLogxK

M3 - Article

C2 - 7180828

AN - SCOPUS:0020403763

VL - 5

SP - 501

EP - 503

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -